After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Under proposed transaction's terms, Horizon Pharma would acquire all outstanding shares of Depomed for $29.25 each in an all-stock transaction, a 42% premium to its closing price on Monday.
Large pharmas continued the shopping spree, paying no attention to whispers of a biotech bubble.
Stocks recapture positive territory for the year on a spate of pharma deals, as well as positive news from the Fed and China.
Stocks recapture positive territory for the year.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.